Free Trial
OTCMKTS:NSPX

Inspyr Therapeutics (NSPX) Stock Price, News & Analysis

About Inspyr Therapeutics Stock (OTCMKTS:NSPX)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
29.64 million shs
Average Volume
13.19 million shs
Market Capitalization
$1.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Inspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.

Receive NSPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inspyr Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NSPX Stock News Headlines

EWTX Edgewise Therapeutics, Inc.
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…
See More Headlines

NSPX Stock Analysis - Frequently Asked Questions

Inspyr Therapeutics, Inc. (OTCMKTS:NSPX) announced its earnings results on Monday, August, 14th. The company reported ($26.25) earnings per share for the quarter.

Inspyr Therapeutics shares reverse split before market open on Tuesday, October 12th 2021. The 1-75 reverse split was announced on Tuesday, October 12th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 12th 2021. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Shares of NSPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Inspyr Therapeutics investors own include Stem (STEM), Hon Hai Precision Industry (HNHPF), iBio (IBIO), Knight-Swift Transportation (KNX), Blink Charging (BLNK), BIO-key International (BKYI) and BIOLASE (BIOL).

Company Calendar

Last Earnings
8/14/2017
Today
11/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:NSPX
Fax
N/A
Employees
1
Year Founded
N/A

Profitability

Net Income
$-6,300,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.07) per share

Miscellaneous

Free Float
N/A
Market Cap
$1.47 million
Optionable
Not Optionable
Beta
-17.33
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (OTCMKTS:NSPX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners